Dynavax Technologies (DVAX) Q4 2023 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/02/22/dynavax-technologies-dvax-q4-2023-earnings-call-tr/?source=iedfolrf0000001
Feb 22, 2024 - DVAX earnings call for the period ending December 31, 2023.
0
Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4
https://www.zacks.com/stock/news/2230460/dynavax-technologies-dvax-reports-break-even-earnings-for-q4?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2230460
Feb 22, 2024 - Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 100% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Dynavax Technologies (DVAX) Is a Great Choice for 'Trend' Investors, Here's Why
https://www.zacks.com/stock/news/2206175/dynavax-technologies-dvax-is-a-great-choice-for-trend-investors-here-s-why?cid=CS-ZC-FT-tale_of_the_tape|recent_price_strength_screen-2206175
Jan 05, 2024 - Dynavax Technologies (DVAX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
0
Collegium (COLL) Shares Rise on Financial Outlook for 2024
https://www.zacks.com/stock/news/2205736/collegium-coll-shares-rise-on-financial-outlook-for-2024?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2205736
Jan 04, 2024 - Collegium (COLL) reports financial guidance for full-year 2024 and business updates. Shares of the company rise on the same.
0
Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO
https://www.zacks.com/stock/news/2205675/assertio-asrt-shares-fall-as-dan-peisert-steps-down-as-ceo?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2205675
Jan 04, 2024 - Assertio (ASRT) appoints Heather Mason as its interim CEO as its current CEO, Dan Peisert, steps down from his role. Shares of the company fall on the same.
0
Voyager (VYGR) Gains on Gene Therapy Deal With Novartis
https://www.zacks.com/stock/news/2205112/voyager-vygr-gains-on-gene-therapy-deal-with-novartis?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2205112
Jan 03, 2024 - Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.
0
3 Biotech Stocks Most Wall Street Analysts Are Bullish About
https://www.zacks.com/stock/news/2199324/3-biotech-stocks-most-wall-street-analysts-are-bullish-about?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199324
Dec 18, 2023 - Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.
0
Vertex (VRTX) Hits Record High on Non-Opioid Pain Drug Data
https://www.zacks.com/stock/news/2197830/vertex-vrtx-hits-record-high-on-non-opioid-pain-drug-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2197830
Dec 14, 2023 - Vertex (VRTX) stock hits a 52-week high after announcing encouraging data from a phase II study on non-opioid pain medicine, VX-548, for treating painful diabetic peripheral neuropathy.
0
Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate
https://www.zacks.com/stock/news/2195671/regeneron-regn-posts-positive-data-on-blood-cancer-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195671
Dec 08, 2023 - Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.
0
Novartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug
https://www.zacks.com/stock/news/2194094/novartis-nvs-gets-fda-nod-for-rare-blood-disorder-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2194094
Dec 06, 2023 - Novartis (NVS) obtains FDA approval for Fabhalta, the first oral monotherapy for treating adults with PNH.
0
Pages: 12
Page 1